Wedekind, M. F., Akshintala, S., Widemann, B. C., Minard, C., Militano, O., Hall, D., Bradley, Z., Reid, J. M., Pressey, J. G., Sharon, E., Foster, J. H., Fox, E., Weigel, B. (2025). Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2695